Evolus, Inc. (NASDAQ:EOLS) Receives $20.80 Consensus Target Price from Analysts

Evolus, Inc. (NASDAQ:EOLS) has earned a consensus rating of “Moderate Buy” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $20.80.

Several research firms have recently issued reports on EOLS. BTIG Research reissued a “buy” rating and set a $18.00 target price on shares of Evolus in a research note on Monday, September 8th. Mizuho reduced their price target on Evolus from $20.00 to $19.00 and set an “outperform” rating for the company in a report on Monday, December 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Evolus in a report on Monday, December 8th. Finally, Wall Street Zen upgraded Evolus from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th.

Institutional Investors Weigh In On Evolus

Several institutional investors and hedge funds have recently added to or reduced their stakes in EOLS. Krensavage Asset Management LLC acquired a new position in Evolus during the third quarter worth about $614,000. Woodline Partners LP increased its holdings in shares of Evolus by 92.2% in the third quarter. Woodline Partners LP now owns 393,222 shares of the company’s stock valued at $2,414,000 after purchasing an additional 188,660 shares during the last quarter. XTX Topco Ltd lifted its position in Evolus by 71.0% during the third quarter. XTX Topco Ltd now owns 140,773 shares of the company’s stock worth $864,000 after buying an additional 58,426 shares in the last quarter. Wexford Capital LP acquired a new position in Evolus during the third quarter worth $37,000. Finally, Prelude Capital Management LLC acquired a new position in Evolus during the third quarter worth $217,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Price Performance

Shares of NASDAQ EOLS opened at $7.06 on Wednesday. The stock has a market capitalization of $457.37 million, a price-to-earnings ratio of -7.67 and a beta of 0.87. The firm’s 50 day simple moving average is $6.85 and its 200-day simple moving average is $7.65. Evolus has a 12 month low of $5.71 and a 12 month high of $17.12.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. The firm had revenue of $68.97 million for the quarter, compared to the consensus estimate of $91.23 million. Evolus had a negative net margin of 20.49% and a negative return on equity of 759.04%. Analysts anticipate that Evolus will post -0.61 earnings per share for the current fiscal year.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.